Anti HPV E7 TCR

Drug Profile

Anti HPV E7 TCR

Alternative Names: anti-HPV016 E7 TCR; E7 TCR gene therapy; E7-TCR; HPV-16 E7 TCR

Latest Information Update: 26 Aug 2016

Price : $50

At a glance

  • Originator National Cancer Institute (USA)
  • Developer Kite Pharma; National Cancer Institute (USA)
  • Class Gene therapies; T lymphocyte cell therapies
  • Mechanism of Action Gene transference; Human papillomavirus E7 protein modulators; T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Cervical cancer; Head and neck cancer; Urogenital cancer

Most Recent Events

  • 01 Jul 2016 Phase-I clinical trials in Cervical cancer in USA (IV) (NCT02858310)
  • 01 Jul 2016 Phase-I clinical trials in Urogenital cancer in USA (IV) (NCT02858310)
  • 01 Jul 2016 Phase-I clinical trials in Head and neck cancer in USA (IV) (NCT02858310)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top